nodes	percent_of_prediction	percent_of_DWPC	metapath
Nortriptyline—ORM1—Vismodegib—skin cancer	0.152	0.191	CbGbCtD
Nortriptyline—ORM1—Vemurafenib—skin cancer	0.12	0.151	CbGbCtD
Nortriptyline—ALB—Vismodegib—skin cancer	0.0638	0.0802	CbGbCtD
Nortriptyline—CYP1A2—Imiquimod—skin cancer	0.055	0.0692	CbGbCtD
Nortriptyline—ALB—Vemurafenib—skin cancer	0.0504	0.0634	CbGbCtD
Nortriptyline—CYP2C19—Vismodegib—skin cancer	0.0413	0.052	CbGbCtD
Nortriptyline—CYP2E1—Dacarbazine—skin cancer	0.04	0.0502	CbGbCtD
Nortriptyline—CYP2C9—Vismodegib—skin cancer	0.0344	0.0432	CbGbCtD
Nortriptyline—CYP1A2—Vemurafenib—skin cancer	0.0302	0.0379	CbGbCtD
Nortriptyline—CYP3A4—Imiquimod—skin cancer	0.0288	0.0362	CbGbCtD
Nortriptyline—CYP3A4—Temozolomide—skin cancer	0.0288	0.0362	CbGbCtD
Nortriptyline—CYP2D6—Vemurafenib—skin cancer	0.0248	0.0312	CbGbCtD
Nortriptyline—CYP1A2—Dacarbazine—skin cancer	0.0231	0.0291	CbGbCtD
Nortriptyline—ALB—Fluorouracil—skin cancer	0.0226	0.0285	CbGbCtD
Nortriptyline—CYP3A4—Vismodegib—skin cancer	0.02	0.0251	CbGbCtD
Nortriptyline—CYP3A4—Vemurafenib—skin cancer	0.0158	0.0199	CbGbCtD
Nortriptyline—CYP3A5—Docetaxel—skin cancer	0.0139	0.0175	CbGbCtD
Nortriptyline—CYP1A2—Fluorouracil—skin cancer	0.0135	0.017	CbGbCtD
Nortriptyline—CYP2C9—Fluorouracil—skin cancer	0.0122	0.0153	CbGbCtD
Nortriptyline—CYP3A4—Docetaxel—skin cancer	0.00542	0.00682	CbGbCtD
Nortriptyline—CHRM3—muscle of abdomen—skin cancer	0.00496	0.106	CbGeAlD
Nortriptyline—HRH1—nose—skin cancer	0.00383	0.0818	CbGeAlD
Nortriptyline—CHRM5—skin epidermis—skin cancer	0.00324	0.0692	CbGeAlD
Nortriptyline—SLC6A2—nerve—skin cancer	0.00153	0.0326	CbGeAlD
Nortriptyline—HTR2A—hindlimb—skin cancer	0.00151	0.0322	CbGeAlD
Nortriptyline—DRD2—nerve—skin cancer	0.00139	0.0297	CbGeAlD
Nortriptyline—HTR2A—appendage—skin cancer	0.00129	0.0276	CbGeAlD
Nortriptyline—CHRM5—epithelium—skin cancer	0.00106	0.0225	CbGeAlD
Nortriptyline—CHRM5—skin of body—skin cancer	0.001	0.0214	CbGeAlD
Nortriptyline—ADRA1D—epithelium—skin cancer	0.000944	0.0202	CbGeAlD
Nortriptyline—HTR2A—nerve—skin cancer	0.000917	0.0196	CbGeAlD
Nortriptyline—PTGS1—endothelium—skin cancer	0.000866	0.0185	CbGeAlD
Nortriptyline—CHRM4—head—skin cancer	0.000839	0.0179	CbGeAlD
Nortriptyline—PTGS1—blood vessel—skin cancer	0.000798	0.017	CbGeAlD
Nortriptyline—HTR2A—endothelium—skin cancer	0.000781	0.0167	CbGeAlD
Nortriptyline—HTR6—head—skin cancer	0.000751	0.016	CbGeAlD
Nortriptyline—HTR2A—blood vessel—skin cancer	0.00072	0.0154	CbGeAlD
Nortriptyline—ADRA1D—female reproductive system—skin cancer	0.000701	0.015	CbGeAlD
Nortriptyline—CYP1A2—nipple—skin cancer	0.000666	0.0142	CbGeAlD
Nortriptyline—CHRM5—head—skin cancer	0.000656	0.014	CbGeAlD
Nortriptyline—HRH1—nipple—skin cancer	0.000623	0.0133	CbGeAlD
Nortriptyline—ADRA1B—head—skin cancer	0.000599	0.0128	CbGeAlD
Nortriptyline—ADRA1D—head—skin cancer	0.000586	0.0125	CbGeAlD
Nortriptyline—ORM1—female reproductive system—skin cancer	0.000578	0.0123	CbGeAlD
Nortriptyline—PTGS1—nipple—skin cancer	0.000577	0.0123	CbGeAlD
Nortriptyline—Agitation—Imiquimod—skin cancer	0.000557	0.00382	CcSEcCtD
Nortriptyline—Pancytopenia—Dactinomycin—skin cancer	0.000548	0.00375	CcSEcCtD
Nortriptyline—Malaise—Imiquimod—skin cancer	0.000547	0.00375	CcSEcCtD
Nortriptyline—Syncope—Imiquimod—skin cancer	0.000544	0.00373	CcSEcCtD
Nortriptyline—Acute coronary syndrome—Bleomycin—skin cancer	0.000544	0.00373	CcSEcCtD
Nortriptyline—Hypotension—Vemurafenib—skin cancer	0.000542	0.00372	CcSEcCtD
Nortriptyline—ADRA1A—epithelium—skin cancer	0.000542	0.0116	CbGeAlD
Nortriptyline—Myocardial infarction—Bleomycin—skin cancer	0.000541	0.0037	CcSEcCtD
Nortriptyline—Stomatitis—Bleomycin—skin cancer	0.000538	0.00368	CcSEcCtD
Nortriptyline—Palpitations—Imiquimod—skin cancer	0.000536	0.00367	CcSEcCtD
Nortriptyline—Loss of consciousness—Imiquimod—skin cancer	0.000533	0.00365	CcSEcCtD
Nortriptyline—Irritability—Fluorouracil—skin cancer	0.000531	0.00364	CcSEcCtD
Nortriptyline—Convulsion—Imiquimod—skin cancer	0.000526	0.0036	CcSEcCtD
Nortriptyline—Hypertension—Imiquimod—skin cancer	0.000524	0.00359	CcSEcCtD
Nortriptyline—Ataxia—Fluorouracil—skin cancer	0.000523	0.00358	CcSEcCtD
Nortriptyline—HTR2C—female reproductive system—skin cancer	0.000519	0.0111	CbGeAlD
Nortriptyline—HTR2A—neck—skin cancer	0.000515	0.011	CbGeAlD
Nortriptyline—Anxiety—Imiquimod—skin cancer	0.000515	0.00353	CcSEcCtD
Nortriptyline—Discomfort—Imiquimod—skin cancer	0.00051	0.0035	CcSEcCtD
Nortriptyline—Sweating increased—Temozolomide—skin cancer	0.000508	0.00348	CcSEcCtD
Nortriptyline—Dry mouth—Imiquimod—skin cancer	0.000505	0.00346	CcSEcCtD
Nortriptyline—Decreased appetite—Vemurafenib—skin cancer	0.000505	0.00346	CcSEcCtD
Nortriptyline—Stomatitis—Dactinomycin—skin cancer	0.000501	0.00344	CcSEcCtD
Nortriptyline—Fatigue—Vemurafenib—skin cancer	0.0005	0.00343	CcSEcCtD
Nortriptyline—Constipation—Vemurafenib—skin cancer	0.000496	0.0034	CcSEcCtD
Nortriptyline—Pancytopenia—Temozolomide—skin cancer	0.000495	0.0034	CcSEcCtD
Nortriptyline—Oedema—Imiquimod—skin cancer	0.000495	0.00339	CcSEcCtD
Nortriptyline—Hypoaesthesia—Bleomycin—skin cancer	0.000493	0.00338	CcSEcCtD
Nortriptyline—SLC6A4—female reproductive system—skin cancer	0.000492	0.0105	CbGeAlD
Nortriptyline—CHRM1—female reproductive system—skin cancer	0.00049	0.0105	CbGeAlD
Nortriptyline—Shock—Imiquimod—skin cancer	0.000487	0.00334	CcSEcCtD
Nortriptyline—Tachycardia—Imiquimod—skin cancer	0.000483	0.00331	CcSEcCtD
Nortriptyline—Pollakiuria—Temozolomide—skin cancer	0.000482	0.0033	CcSEcCtD
Nortriptyline—Erectile dysfunction—Temozolomide—skin cancer	0.00048	0.00329	CcSEcCtD
Nortriptyline—Agranulocytosis—Dactinomycin—skin cancer	0.00048	0.00329	CcSEcCtD
Nortriptyline—Hyperhidrosis—Imiquimod—skin cancer	0.000479	0.00328	CcSEcCtD
Nortriptyline—Eosinophilia—Fluorouracil—skin cancer	0.000476	0.00326	CcSEcCtD
Nortriptyline—Weight increased—Temozolomide—skin cancer	0.000475	0.00325	CcSEcCtD
Nortriptyline—Weight decreased—Temozolomide—skin cancer	0.000472	0.00323	CcSEcCtD
Nortriptyline—Anorexia—Imiquimod—skin cancer	0.000472	0.00323	CcSEcCtD
Nortriptyline—Hepatitis—Dactinomycin—skin cancer	0.000462	0.00316	CcSEcCtD
Nortriptyline—Flushing—Bleomycin—skin cancer	0.000459	0.00315	CcSEcCtD
Nortriptyline—Body temperature increased—Vemurafenib—skin cancer	0.000459	0.00314	CcSEcCtD
Nortriptyline—Pancytopenia—Fluorouracil—skin cancer	0.000456	0.00313	CcSEcCtD
Nortriptyline—Neuropathy peripheral—Temozolomide—skin cancer	0.000456	0.00312	CcSEcCtD
Nortriptyline—Stomatitis—Temozolomide—skin cancer	0.000453	0.00311	CcSEcCtD
Nortriptyline—CHRM2—head—skin cancer	0.00045	0.0096	CbGeAlD
Nortriptyline—Insomnia—Imiquimod—skin cancer	0.000448	0.00307	CcSEcCtD
Nortriptyline—Paraesthesia—Imiquimod—skin cancer	0.000445	0.00305	CcSEcCtD
Nortriptyline—HRH1—connective tissue—skin cancer	0.000442	0.00944	CbGeAlD
Nortriptyline—Somnolence—Imiquimod—skin cancer	0.00044	0.00302	CcSEcCtD
Nortriptyline—CHRM3—female reproductive system—skin cancer	0.000439	0.00936	CbGeAlD
Nortriptyline—Alopecia—Bleomycin—skin cancer	0.000437	0.003	CcSEcCtD
Nortriptyline—Dyspepsia—Imiquimod—skin cancer	0.000436	0.00299	CcSEcCtD
Nortriptyline—HTR2C—head—skin cancer	0.000434	0.00926	CbGeAlD
Nortriptyline—SLC6A2—female reproductive system—skin cancer	0.000433	0.00925	CbGeAlD
Nortriptyline—Decreased appetite—Imiquimod—skin cancer	0.00043	0.00295	CcSEcCtD
Nortriptyline—Hot flush—Docetaxel—skin cancer	0.000429	0.00294	CcSEcCtD
Nortriptyline—Flushing—Dactinomycin—skin cancer	0.000428	0.00294	CcSEcCtD
Nortriptyline—Hypersensitivity—Vemurafenib—skin cancer	0.000428	0.00293	CcSEcCtD
Nortriptyline—Fatigue—Imiquimod—skin cancer	0.000427	0.00292	CcSEcCtD
Nortriptyline—Menopausal symptoms—Docetaxel—skin cancer	0.000425	0.00292	CcSEcCtD
Nortriptyline—Acute coronary syndrome—Fluorouracil—skin cancer	0.000422	0.0029	CcSEcCtD
Nortriptyline—Myocardial infarction—Fluorouracil—skin cancer	0.00042	0.00288	CcSEcCtD
Nortriptyline—Neuropathy peripheral—Fluorouracil—skin cancer	0.00042	0.00288	CcSEcCtD
Nortriptyline—HRH1—epithelium—skin cancer	0.00042	0.00896	CbGeAlD
Nortriptyline—Stomatitis—Fluorouracil—skin cancer	0.000418	0.00286	CcSEcCtD
Nortriptyline—ADRA1A—lymphoid tissue—skin cancer	0.000418	0.00891	CbGeAlD
Nortriptyline—Hepatitis—Temozolomide—skin cancer	0.000418	0.00286	CcSEcCtD
Nortriptyline—Asthenia—Vemurafenib—skin cancer	0.000416	0.00285	CcSEcCtD
Nortriptyline—Hallucination—Temozolomide—skin cancer	0.000415	0.00285	CcSEcCtD
Nortriptyline—Hypoaesthesia—Temozolomide—skin cancer	0.000415	0.00285	CcSEcCtD
Nortriptyline—Oedema peripheral—Temozolomide—skin cancer	0.000411	0.00282	CcSEcCtD
Nortriptyline—SLC6A4—head—skin cancer	0.000411	0.00878	CbGeAlD
Nortriptyline—Pruritus—Vemurafenib—skin cancer	0.000411	0.00281	CcSEcCtD
Nortriptyline—CHRM1—head—skin cancer	0.00041	0.00874	CbGeAlD
Nortriptyline—PTGS1—connective tissue—skin cancer	0.000409	0.00874	CbGeAlD
Nortriptyline—Alopecia—Dactinomycin—skin cancer	0.000408	0.0028	CcSEcCtD
Nortriptyline—Feeling abnormal—Imiquimod—skin cancer	0.000408	0.0028	CcSEcCtD
Nortriptyline—Agranulocytosis—Fluorouracil—skin cancer	0.0004	0.00274	CcSEcCtD
Nortriptyline—Ill-defined disorder—Bleomycin—skin cancer	0.0004	0.00274	CcSEcCtD
Nortriptyline—Diarrhoea—Vemurafenib—skin cancer	0.000397	0.00272	CcSEcCtD
Nortriptyline—Urticaria—Imiquimod—skin cancer	0.000393	0.0027	CcSEcCtD
Nortriptyline—Body temperature increased—Imiquimod—skin cancer	0.000391	0.00268	CcSEcCtD
Nortriptyline—Abdominal pain—Imiquimod—skin cancer	0.000391	0.00268	CcSEcCtD
Nortriptyline—Eye disorder—Temozolomide—skin cancer	0.00039	0.00267	CcSEcCtD
Nortriptyline—Tinnitus—Temozolomide—skin cancer	0.000389	0.00267	CcSEcCtD
Nortriptyline—PTGS1—epithelium—skin cancer	0.000389	0.00829	CbGeAlD
Nortriptyline—Malaise—Bleomycin—skin cancer	0.000389	0.00266	CcSEcCtD
Nortriptyline—Flushing—Temozolomide—skin cancer	0.000388	0.00266	CcSEcCtD
Nortriptyline—Leukopenia—Bleomycin—skin cancer	0.000386	0.00264	CcSEcCtD
Nortriptyline—Dizziness—Vemurafenib—skin cancer	0.000384	0.00263	CcSEcCtD
Nortriptyline—Hypoaesthesia—Fluorouracil—skin cancer	0.000383	0.00262	CcSEcCtD
Nortriptyline—Ataxia—Docetaxel—skin cancer	0.000377	0.00259	CcSEcCtD
Nortriptyline—Ill-defined disorder—Dactinomycin—skin cancer	0.000373	0.00256	CcSEcCtD
Nortriptyline—PTGS1—skin of body—skin cancer	0.00037	0.00789	CbGeAlD
Nortriptyline—HTR2A—connective tissue—skin cancer	0.000369	0.00788	CbGeAlD
Nortriptyline—Vomiting—Vemurafenib—skin cancer	0.000369	0.00253	CcSEcCtD
Nortriptyline—Alopecia—Temozolomide—skin cancer	0.000369	0.00253	CcSEcCtD
Nortriptyline—Orthostatic hypotension—Docetaxel—skin cancer	0.000367	0.00251	CcSEcCtD
Nortriptyline—CHRM3—head—skin cancer	0.000367	0.00782	CbGeAlD
Nortriptyline—Rash—Vemurafenib—skin cancer	0.000366	0.00251	CcSEcCtD
Nortriptyline—Dermatitis—Vemurafenib—skin cancer	0.000366	0.00251	CcSEcCtD
Nortriptyline—HTR1A—head—skin cancer	0.000365	0.00779	CbGeAlD
Nortriptyline—Hypersensitivity—Imiquimod—skin cancer	0.000365	0.0025	CcSEcCtD
Nortriptyline—HRH1—mammalian vulva—skin cancer	0.000364	0.00777	CbGeAlD
Nortriptyline—Headache—Vemurafenib—skin cancer	0.000364	0.00249	CcSEcCtD
Nortriptyline—Discomfort—Bleomycin—skin cancer	0.000362	0.00248	CcSEcCtD
Nortriptyline—Malaise—Dactinomycin—skin cancer	0.000362	0.00248	CcSEcCtD
Nortriptyline—SLC6A2—head—skin cancer	0.000362	0.00773	CbGeAlD
Nortriptyline—Leukopenia—Dactinomycin—skin cancer	0.00036	0.00247	CcSEcCtD
Nortriptyline—Dysgeusia—Temozolomide—skin cancer	0.000356	0.00244	CcSEcCtD
Nortriptyline—Asthenia—Imiquimod—skin cancer	0.000355	0.00243	CcSEcCtD
Nortriptyline—Confusional state—Bleomycin—skin cancer	0.000355	0.00243	CcSEcCtD
Nortriptyline—Oedema—Bleomycin—skin cancer	0.000352	0.00241	CcSEcCtD
Nortriptyline—HTR2A—epithelium—skin cancer	0.000351	0.00748	CbGeAlD
Nortriptyline—Pruritus—Imiquimod—skin cancer	0.00035	0.0024	CcSEcCtD
Nortriptyline—Nausea—Vemurafenib—skin cancer	0.000345	0.00236	CcSEcCtD
Nortriptyline—Thrombocytopenia—Bleomycin—skin cancer	0.000344	0.00236	CcSEcCtD
Nortriptyline—Arrhythmia—Fluorouracil—skin cancer	0.000344	0.00236	CcSEcCtD
Nortriptyline—Vision blurred—Temozolomide—skin cancer	0.000343	0.00235	CcSEcCtD
Nortriptyline—Tremor—Temozolomide—skin cancer	0.000341	0.00233	CcSEcCtD
Nortriptyline—Alopecia—Fluorouracil—skin cancer	0.00034	0.00233	CcSEcCtD
Nortriptyline—Diarrhoea—Imiquimod—skin cancer	0.000339	0.00232	CcSEcCtD
Nortriptyline—Discomfort—Dactinomycin—skin cancer	0.000338	0.00232	CcSEcCtD
Nortriptyline—ORM1—lymph node—skin cancer	0.000338	0.00721	CbGeAlD
Nortriptyline—Ill-defined disorder—Temozolomide—skin cancer	0.000337	0.00231	CcSEcCtD
Nortriptyline—PTGS1—mammalian vulva—skin cancer	0.000337	0.00719	CbGeAlD
Nortriptyline—ADRA1A—head—skin cancer	0.000337	0.00718	CbGeAlD
Nortriptyline—Anorexia—Bleomycin—skin cancer	0.000335	0.0023	CcSEcCtD
Nortriptyline—Agitation—Temozolomide—skin cancer	0.000334	0.00229	CcSEcCtD
Nortriptyline—DRD2—head—skin cancer	0.00033	0.00704	CbGeAlD
Nortriptyline—Pancytopenia—Docetaxel—skin cancer	0.000329	0.00226	CcSEcCtD
Nortriptyline—Hypotension—Bleomycin—skin cancer	0.000329	0.00225	CcSEcCtD
Nortriptyline—Oedema—Dactinomycin—skin cancer	0.000328	0.00225	CcSEcCtD
Nortriptyline—Malaise—Temozolomide—skin cancer	0.000328	0.00225	CcSEcCtD
Nortriptyline—Dizziness—Imiquimod—skin cancer	0.000327	0.00224	CcSEcCtD
Nortriptyline—Leukopenia—Temozolomide—skin cancer	0.000325	0.00223	CcSEcCtD
Nortriptyline—Palpitations—Temozolomide—skin cancer	0.000321	0.0022	CcSEcCtD
Nortriptyline—Thrombocytopenia—Dactinomycin—skin cancer	0.000321	0.0022	CcSEcCtD
Nortriptyline—CYP2C9—female reproductive system—skin cancer	0.000316	0.00675	CbGeAlD
Nortriptyline—Paraesthesia—Bleomycin—skin cancer	0.000316	0.00216	CcSEcCtD
Nortriptyline—Weight increased—Docetaxel—skin cancer	0.000316	0.00216	CcSEcCtD
Nortriptyline—Vision blurred—Fluorouracil—skin cancer	0.000316	0.00216	CcSEcCtD
Nortriptyline—Convulsion—Temozolomide—skin cancer	0.000315	0.00216	CcSEcCtD
Nortriptyline—Vomiting—Imiquimod—skin cancer	0.000315	0.00216	CcSEcCtD
Nortriptyline—Weight decreased—Docetaxel—skin cancer	0.000314	0.00215	CcSEcCtD
Nortriptyline—Hypertension—Temozolomide—skin cancer	0.000314	0.00215	CcSEcCtD
Nortriptyline—Anorexia—Dactinomycin—skin cancer	0.000313	0.00214	CcSEcCtD
Nortriptyline—Rash—Imiquimod—skin cancer	0.000312	0.00214	CcSEcCtD
Nortriptyline—HRH1—female reproductive system—skin cancer	0.000312	0.00666	CbGeAlD
Nortriptyline—Dermatitis—Imiquimod—skin cancer	0.000312	0.00214	CcSEcCtD
Nortriptyline—CYP2E1—lymphoid tissue—skin cancer	0.000311	0.00663	CbGeAlD
Nortriptyline—Headache—Imiquimod—skin cancer	0.00031	0.00213	CcSEcCtD
Nortriptyline—Anxiety—Temozolomide—skin cancer	0.000308	0.00211	CcSEcCtD
Nortriptyline—Discomfort—Temozolomide—skin cancer	0.000306	0.0021	CcSEcCtD
Nortriptyline—Decreased appetite—Bleomycin—skin cancer	0.000306	0.0021	CcSEcCtD
Nortriptyline—Acute coronary syndrome—Docetaxel—skin cancer	0.000305	0.00209	CcSEcCtD
Nortriptyline—Myocardial infarction—Docetaxel—skin cancer	0.000303	0.00208	CcSEcCtD
Nortriptyline—Neuropathy peripheral—Docetaxel—skin cancer	0.000303	0.00208	CcSEcCtD
Nortriptyline—Dry mouth—Temozolomide—skin cancer	0.000303	0.00207	CcSEcCtD
Nortriptyline—Stomatitis—Docetaxel—skin cancer	0.000302	0.00207	CcSEcCtD
Nortriptyline—Jaundice—Docetaxel—skin cancer	0.000302	0.00207	CcSEcCtD
Nortriptyline—Leukopenia—Fluorouracil—skin cancer	0.0003	0.00205	CcSEcCtD
Nortriptyline—CYP2E1—female reproductive system—skin cancer	0.0003	0.0064	CbGeAlD
Nortriptyline—Confusional state—Temozolomide—skin cancer	0.000299	0.00205	CcSEcCtD
Nortriptyline—Oedema—Temozolomide—skin cancer	0.000297	0.00203	CcSEcCtD
Nortriptyline—ALB—lymph node—skin cancer	0.000296	0.00632	CbGeAlD
Nortriptyline—Nausea—Imiquimod—skin cancer	0.000294	0.00202	CcSEcCtD
Nortriptyline—Thrombocytopenia—Temozolomide—skin cancer	0.00029	0.00199	CcSEcCtD
Nortriptyline—Convulsion—Fluorouracil—skin cancer	0.00029	0.00199	CcSEcCtD
Nortriptyline—Feeling abnormal—Bleomycin—skin cancer	0.00029	0.00199	CcSEcCtD
Nortriptyline—PTGS1—female reproductive system—skin cancer	0.000289	0.00616	CbGeAlD
Nortriptyline—Agranulocytosis—Docetaxel—skin cancer	0.000289	0.00198	CcSEcCtD
Nortriptyline—Hyperhidrosis—Temozolomide—skin cancer	0.000287	0.00197	CcSEcCtD
Nortriptyline—Decreased appetite—Dactinomycin—skin cancer	0.000285	0.00195	CcSEcCtD
Nortriptyline—Fatigue—Dactinomycin—skin cancer	0.000283	0.00194	CcSEcCtD
Nortriptyline—Anorexia—Temozolomide—skin cancer	0.000283	0.00194	CcSEcCtD
Nortriptyline—Discomfort—Fluorouracil—skin cancer	0.000282	0.00193	CcSEcCtD
Nortriptyline—Urticaria—Bleomycin—skin cancer	0.000279	0.00191	CcSEcCtD
Nortriptyline—Body temperature increased—Bleomycin—skin cancer	0.000278	0.00191	CcSEcCtD
Nortriptyline—Hepatitis—Docetaxel—skin cancer	0.000278	0.0019	CcSEcCtD
Nortriptyline—Hypoaesthesia—Docetaxel—skin cancer	0.000276	0.00189	CcSEcCtD
Nortriptyline—Confusional state—Fluorouracil—skin cancer	0.000276	0.00189	CcSEcCtD
Nortriptyline—Oedema peripheral—Docetaxel—skin cancer	0.000274	0.00187	CcSEcCtD
Nortriptyline—Oedema—Fluorouracil—skin cancer	0.000273	0.00187	CcSEcCtD
Nortriptyline—Feeling abnormal—Dactinomycin—skin cancer	0.00027	0.00185	CcSEcCtD
Nortriptyline—Insomnia—Temozolomide—skin cancer	0.000268	0.00184	CcSEcCtD
Nortriptyline—Thrombocytopenia—Fluorouracil—skin cancer	0.000268	0.00183	CcSEcCtD
Nortriptyline—Tachycardia—Fluorouracil—skin cancer	0.000267	0.00183	CcSEcCtD
Nortriptyline—Paraesthesia—Temozolomide—skin cancer	0.000266	0.00183	CcSEcCtD
Nortriptyline—Somnolence—Temozolomide—skin cancer	0.000264	0.00181	CcSEcCtD
Nortriptyline—Dyspepsia—Temozolomide—skin cancer	0.000261	0.00179	CcSEcCtD
Nortriptyline—Anorexia—Fluorouracil—skin cancer	0.000261	0.00179	CcSEcCtD
Nortriptyline—HRH1—head—skin cancer	0.000261	0.00556	CbGeAlD
Nortriptyline—HTR2A—female reproductive system—skin cancer	0.00026	0.00556	CbGeAlD
Nortriptyline—Eye disorder—Docetaxel—skin cancer	0.00026	0.00178	CcSEcCtD
Nortriptyline—Abdominal pain—Dactinomycin—skin cancer	0.000259	0.00178	CcSEcCtD
Nortriptyline—Body temperature increased—Dactinomycin—skin cancer	0.000259	0.00178	CcSEcCtD
Nortriptyline—Hypersensitivity—Bleomycin—skin cancer	0.000259	0.00178	CcSEcCtD
Nortriptyline—Decreased appetite—Temozolomide—skin cancer	0.000258	0.00177	CcSEcCtD
Nortriptyline—Flushing—Docetaxel—skin cancer	0.000258	0.00177	CcSEcCtD
Nortriptyline—Fatigue—Temozolomide—skin cancer	0.000256	0.00175	CcSEcCtD
Nortriptyline—Hypotension—Fluorouracil—skin cancer	0.000255	0.00175	CcSEcCtD
Nortriptyline—Constipation—Temozolomide—skin cancer	0.000254	0.00174	CcSEcCtD
Nortriptyline—SLC6A2—lymph node—skin cancer	0.000253	0.00541	CbGeAlD
Nortriptyline—Asthenia—Bleomycin—skin cancer	0.000252	0.00173	CcSEcCtD
Nortriptyline—CYP2E1—head—skin cancer	0.00025	0.00534	CbGeAlD
Nortriptyline—Pruritus—Bleomycin—skin cancer	0.000249	0.00171	CcSEcCtD
Nortriptyline—Arrhythmia—Docetaxel—skin cancer	0.000248	0.0017	CcSEcCtD
Nortriptyline—Insomnia—Fluorouracil—skin cancer	0.000247	0.00169	CcSEcCtD
Nortriptyline—Paraesthesia—Fluorouracil—skin cancer	0.000245	0.00168	CcSEcCtD
Nortriptyline—Alopecia—Docetaxel—skin cancer	0.000245	0.00168	CcSEcCtD
Nortriptyline—Feeling abnormal—Temozolomide—skin cancer	0.000244	0.00168	CcSEcCtD
Nortriptyline—Somnolence—Fluorouracil—skin cancer	0.000243	0.00167	CcSEcCtD
Nortriptyline—Hypersensitivity—Dactinomycin—skin cancer	0.000242	0.00166	CcSEcCtD
Nortriptyline—PTGS1—head—skin cancer	0.000241	0.00515	CbGeAlD
Nortriptyline—CYP3A4—female reproductive system—skin cancer	0.000241	0.00515	CbGeAlD
Nortriptyline—Dyspepsia—Fluorouracil—skin cancer	0.000241	0.00165	CcSEcCtD
Nortriptyline—Decreased appetite—Fluorouracil—skin cancer	0.000238	0.00163	CcSEcCtD
Nortriptyline—CYP2D6—female reproductive system—skin cancer	0.000237	0.00506	CbGeAlD
Nortriptyline—Dysgeusia—Docetaxel—skin cancer	0.000237	0.00162	CcSEcCtD
Nortriptyline—Urticaria—Temozolomide—skin cancer	0.000236	0.00162	CcSEcCtD
Nortriptyline—Asthenia—Dactinomycin—skin cancer	0.000235	0.00161	CcSEcCtD
Nortriptyline—Body temperature increased—Temozolomide—skin cancer	0.000235	0.00161	CcSEcCtD
Nortriptyline—Abdominal pain—Temozolomide—skin cancer	0.000235	0.00161	CcSEcCtD
Nortriptyline—Feeling abnormal—Fluorouracil—skin cancer	0.000225	0.00154	CcSEcCtD
Nortriptyline—Diarrhoea—Dactinomycin—skin cancer	0.000224	0.00154	CcSEcCtD
Nortriptyline—Vomiting—Bleomycin—skin cancer	0.000224	0.00153	CcSEcCtD
Nortriptyline—Rash—Bleomycin—skin cancer	0.000222	0.00152	CcSEcCtD
Nortriptyline—Dermatitis—Bleomycin—skin cancer	0.000222	0.00152	CcSEcCtD
Nortriptyline—Hypersensitivity—Temozolomide—skin cancer	0.000219	0.0015	CcSEcCtD
Nortriptyline—HTR2A—head—skin cancer	0.000218	0.00464	CbGeAlD
Nortriptyline—Urticaria—Fluorouracil—skin cancer	0.000217	0.00149	CcSEcCtD
Nortriptyline—Syncope—Docetaxel—skin cancer	0.000217	0.00149	CcSEcCtD
Nortriptyline—Leukopenia—Docetaxel—skin cancer	0.000216	0.00148	CcSEcCtD
Nortriptyline—Body temperature increased—Fluorouracil—skin cancer	0.000216	0.00148	CcSEcCtD
Nortriptyline—Palpitations—Docetaxel—skin cancer	0.000214	0.00146	CcSEcCtD
Nortriptyline—Asthenia—Temozolomide—skin cancer	0.000213	0.00146	CcSEcCtD
Nortriptyline—Loss of consciousness—Docetaxel—skin cancer	0.000212	0.00146	CcSEcCtD
Nortriptyline—Pruritus—Temozolomide—skin cancer	0.00021	0.00144	CcSEcCtD
Nortriptyline—Convulsion—Docetaxel—skin cancer	0.000209	0.00144	CcSEcCtD
Nortriptyline—Nausea—Bleomycin—skin cancer	0.000209	0.00143	CcSEcCtD
Nortriptyline—Hypertension—Docetaxel—skin cancer	0.000209	0.00143	CcSEcCtD
Nortriptyline—Vomiting—Dactinomycin—skin cancer	0.000209	0.00143	CcSEcCtD
Nortriptyline—Rash—Dactinomycin—skin cancer	0.000207	0.00142	CcSEcCtD
Nortriptyline—Diarrhoea—Temozolomide—skin cancer	0.000203	0.00139	CcSEcCtD
Nortriptyline—Hypersensitivity—Fluorouracil—skin cancer	0.000201	0.00138	CcSEcCtD
Nortriptyline—Dry mouth—Docetaxel—skin cancer	0.000201	0.00138	CcSEcCtD
Nortriptyline—Confusional state—Docetaxel—skin cancer	0.000199	0.00136	CcSEcCtD
Nortriptyline—CYP2D6—head—skin cancer	0.000198	0.00423	CbGeAlD
Nortriptyline—Oedema—Docetaxel—skin cancer	0.000197	0.00135	CcSEcCtD
Nortriptyline—Dizziness—Temozolomide—skin cancer	0.000196	0.00134	CcSEcCtD
Nortriptyline—Nausea—Dactinomycin—skin cancer	0.000195	0.00134	CcSEcCtD
Nortriptyline—Shock—Docetaxel—skin cancer	0.000194	0.00133	CcSEcCtD
Nortriptyline—Pruritus—Fluorouracil—skin cancer	0.000193	0.00133	CcSEcCtD
Nortriptyline—Thrombocytopenia—Docetaxel—skin cancer	0.000193	0.00132	CcSEcCtD
Nortriptyline—Tachycardia—Docetaxel—skin cancer	0.000193	0.00132	CcSEcCtD
Nortriptyline—Vomiting—Temozolomide—skin cancer	0.000189	0.00129	CcSEcCtD
Nortriptyline—Anorexia—Docetaxel—skin cancer	0.000188	0.00129	CcSEcCtD
Nortriptyline—Rash—Temozolomide—skin cancer	0.000187	0.00128	CcSEcCtD
Nortriptyline—Diarrhoea—Fluorouracil—skin cancer	0.000187	0.00128	CcSEcCtD
Nortriptyline—Dermatitis—Temozolomide—skin cancer	0.000187	0.00128	CcSEcCtD
Nortriptyline—Headache—Temozolomide—skin cancer	0.000186	0.00127	CcSEcCtD
Nortriptyline—Hypotension—Docetaxel—skin cancer	0.000184	0.00126	CcSEcCtD
Nortriptyline—HRH1—lymph node—skin cancer	0.000182	0.00389	CbGeAlD
Nortriptyline—Dizziness—Fluorouracil—skin cancer	0.000181	0.00124	CcSEcCtD
Nortriptyline—Insomnia—Docetaxel—skin cancer	0.000178	0.00122	CcSEcCtD
Nortriptyline—Paraesthesia—Docetaxel—skin cancer	0.000177	0.00121	CcSEcCtD
Nortriptyline—Nausea—Temozolomide—skin cancer	0.000176	0.00121	CcSEcCtD
Nortriptyline—Somnolence—Docetaxel—skin cancer	0.000175	0.0012	CcSEcCtD
Nortriptyline—Vomiting—Fluorouracil—skin cancer	0.000174	0.00119	CcSEcCtD
Nortriptyline—Dyspepsia—Docetaxel—skin cancer	0.000174	0.00119	CcSEcCtD
Nortriptyline—Rash—Fluorouracil—skin cancer	0.000172	0.00118	CcSEcCtD
Nortriptyline—Dermatitis—Fluorouracil—skin cancer	0.000172	0.00118	CcSEcCtD
Nortriptyline—Decreased appetite—Docetaxel—skin cancer	0.000172	0.00118	CcSEcCtD
Nortriptyline—Headache—Fluorouracil—skin cancer	0.000171	0.00117	CcSEcCtD
Nortriptyline—Fatigue—Docetaxel—skin cancer	0.00017	0.00117	CcSEcCtD
Nortriptyline—PTGS1—lymph node—skin cancer	0.000169	0.0036	CbGeAlD
Nortriptyline—Constipation—Docetaxel—skin cancer	0.000169	0.00116	CcSEcCtD
Nortriptyline—Feeling abnormal—Docetaxel—skin cancer	0.000163	0.00111	CcSEcCtD
Nortriptyline—Nausea—Fluorouracil—skin cancer	0.000162	0.00111	CcSEcCtD
Nortriptyline—Body temperature increased—Docetaxel—skin cancer	0.000156	0.00107	CcSEcCtD
Nortriptyline—Abdominal pain—Docetaxel—skin cancer	0.000156	0.00107	CcSEcCtD
Nortriptyline—Hypersensitivity—Docetaxel—skin cancer	0.000145	0.000996	CcSEcCtD
Nortriptyline—Asthenia—Docetaxel—skin cancer	0.000142	0.00097	CcSEcCtD
Nortriptyline—Pruritus—Docetaxel—skin cancer	0.00014	0.000957	CcSEcCtD
Nortriptyline—Diarrhoea—Docetaxel—skin cancer	0.000135	0.000925	CcSEcCtD
Nortriptyline—Dizziness—Docetaxel—skin cancer	0.00013	0.000894	CcSEcCtD
Nortriptyline—Vomiting—Docetaxel—skin cancer	0.000125	0.00086	CcSEcCtD
Nortriptyline—Rash—Docetaxel—skin cancer	0.000124	0.000852	CcSEcCtD
Nortriptyline—Dermatitis—Docetaxel—skin cancer	0.000124	0.000852	CcSEcCtD
Nortriptyline—Headache—Docetaxel—skin cancer	0.000124	0.000847	CcSEcCtD
Nortriptyline—Nausea—Docetaxel—skin cancer	0.000117	0.000803	CcSEcCtD
Nortriptyline—HTR2C—Signaling Pathways—PTCH1—skin cancer	6.4e-06	0.000541	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—SMO—skin cancer	6.4e-06	0.000541	CbGpPWpGaD
Nortriptyline—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	6.37e-06	0.000538	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—FOXO4—skin cancer	6.34e-06	0.000536	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—PTGER4—skin cancer	6.26e-06	0.000529	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—PTGER4—skin cancer	6.23e-06	0.000526	CbGpPWpGaD
Nortriptyline—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	6.13e-06	0.000518	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—SMO—skin cancer	6.12e-06	0.000518	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—PTCH1—skin cancer	6.12e-06	0.000518	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—CSPG4—skin cancer	6.11e-06	0.000517	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—CSPG4—skin cancer	6.06e-06	0.000512	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—PTGER4—skin cancer	5.96e-06	0.000504	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—SHH—skin cancer	5.95e-06	0.000503	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—RASA1—skin cancer	5.92e-06	0.0005	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—SHH—skin cancer	5.86e-06	0.000495	CbGpPWpGaD
Nortriptyline—CYP2E1—Metabolism—ENO2—skin cancer	5.85e-06	0.000495	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—SHH—skin cancer	5.85e-06	0.000494	CbGpPWpGaD
Nortriptyline—CYP3A5—Metabolism—ENO2—skin cancer	5.84e-06	0.000494	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—SHH—skin cancer	5.83e-06	0.000493	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—RASA1—skin cancer	5.82e-06	0.000492	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—RASA1—skin cancer	5.81e-06	0.000491	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—SHH—skin cancer	5.81e-06	0.000491	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—RASA1—skin cancer	5.79e-06	0.00049	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—RASA1—skin cancer	5.77e-06	0.000488	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—SHH—skin cancer	5.75e-06	0.000486	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—SHH—skin cancer	5.74e-06	0.000485	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—RASA1—skin cancer	5.72e-06	0.000483	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—RASA1—skin cancer	5.7e-06	0.000482	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—SMO—skin cancer	5.65e-06	0.000477	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—PTCH1—skin cancer	5.65e-06	0.000477	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—SMO—skin cancer	5.55e-06	0.00047	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—PTCH1—skin cancer	5.55e-06	0.00047	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—PTCH1—skin cancer	5.54e-06	0.000469	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—SMO—skin cancer	5.54e-06	0.000469	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—FOXO4—skin cancer	5.53e-06	0.000467	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—PTCH1—skin cancer	5.52e-06	0.000467	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—SMO—skin cancer	5.52e-06	0.000467	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—PTCH1—skin cancer	5.51e-06	0.000466	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—SMO—skin cancer	5.51e-06	0.000466	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—FOXO4—skin cancer	5.5e-06	0.000465	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—PTGER4—skin cancer	5.5e-06	0.000465	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—SMO—skin cancer	5.45e-06	0.000461	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—PTCH1—skin cancer	5.45e-06	0.000461	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—PTCH1—skin cancer	5.44e-06	0.00046	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—SMO—skin cancer	5.44e-06	0.00046	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—PTGER4—skin cancer	5.41e-06	0.000457	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—PTGER4—skin cancer	5.4e-06	0.000456	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—PTGER4—skin cancer	5.38e-06	0.000455	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—PTGER4—skin cancer	5.36e-06	0.000453	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—PTGER4—skin cancer	5.31e-06	0.000449	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—PTGER4—skin cancer	5.29e-06	0.000448	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—FOXO4—skin cancer	5.27e-06	0.000445	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—CSPG4—skin cancer	5.18e-06	0.000438	CbGpPWpGaD
Nortriptyline—ALB—Metabolism—ENO2—skin cancer	5.03e-06	0.000425	CbGpPWpGaD
Nortriptyline—HTR6—Signaling Pathways—TERT—skin cancer	4.99e-06	0.000422	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—PLIN2—skin cancer	4.96e-06	0.000419	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—FOXO4—skin cancer	4.85e-06	0.00041	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—FOXO4—skin cancer	4.78e-06	0.000404	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—FOXO4—skin cancer	4.77e-06	0.000403	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—FOXO4—skin cancer	4.75e-06	0.000402	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—FOXO4—skin cancer	4.74e-06	0.0004	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—TERT—skin cancer	4.71e-06	0.000398	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—FOXO4—skin cancer	4.69e-06	0.000396	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—FOXO4—skin cancer	4.68e-06	0.000395	CbGpPWpGaD
Nortriptyline—PTGS1—Metabolism—ERCC2—skin cancer	4.55e-06	0.000385	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—ENO2—skin cancer	4.52e-06	0.000382	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—TERT—skin cancer	4.51e-06	0.000381	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—TERT—skin cancer	4.24e-06	0.000358	CbGpPWpGaD
Nortriptyline—HTR6—Signaling by GPCR—NRAS—skin cancer	4.2e-06	0.000355	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—ENO2—skin cancer	4.15e-06	0.000351	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—ENO2—skin cancer	4.12e-06	0.000348	CbGpPWpGaD
Nortriptyline—CHRM3—Metabolism—ERCC2—skin cancer	4.04e-06	0.000341	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—CSPG4—skin cancer	4e-06	0.000338	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling by GPCR—NRAS—skin cancer	3.96e-06	0.000335	CbGpPWpGaD
Nortriptyline—HTR6—Signaling Pathways—BRAF—skin cancer	3.95e-06	0.000334	CbGpPWpGaD
Nortriptyline—ALB—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.93e-06	0.000333	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling by GPCR—NRAS—skin cancer	3.8e-06	0.000321	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—BRAF—skin cancer	3.73e-06	0.000315	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—TERT—skin cancer	3.69e-06	0.000312	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—TERT—skin cancer	3.67e-06	0.000311	CbGpPWpGaD
Nortriptyline—HTR6—Signaling by GPCR—KRAS—skin cancer	3.62e-06	0.000306	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling by GPCR—NRAS—skin cancer	3.57e-06	0.000302	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—BRAF—skin cancer	3.57e-06	0.000302	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.53e-06	0.000299	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—ENO2—skin cancer	3.52e-06	0.000297	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—TERT—skin cancer	3.52e-06	0.000297	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling by GPCR—KRAS—skin cancer	3.41e-06	0.000288	CbGpPWpGaD
Nortriptyline—CYP2E1—Metabolism—ERCC2—skin cancer	3.4e-06	0.000287	CbGpPWpGaD
Nortriptyline—CYP3A5—Metabolism—ERCC2—skin cancer	3.39e-06	0.000287	CbGpPWpGaD
Nortriptyline—ALB—Hemostasis—NRAS—skin cancer	3.36e-06	0.000284	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—BRAF—skin cancer	3.36e-06	0.000284	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling by GPCR—KRAS—skin cancer	3.27e-06	0.000276	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—TERT—skin cancer	3.24e-06	0.000274	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.22e-06	0.000272	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—TERT—skin cancer	3.19e-06	0.00027	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—TERT—skin cancer	3.18e-06	0.000269	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—TERT—skin cancer	3.17e-06	0.000268	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—TERT—skin cancer	3.16e-06	0.000267	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—TERT—skin cancer	3.13e-06	0.000265	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—TERT—skin cancer	3.12e-06	0.000264	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling by GPCR—NRAS—skin cancer	3.11e-06	0.000263	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling by GPCR—NRAS—skin cancer	3.1e-06	0.000262	CbGpPWpGaD
Nortriptyline—HTR6—Signaling by GPCR—HRAS—skin cancer	3.07e-06	0.00026	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling by GPCR—KRAS—skin cancer	3.07e-06	0.00026	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling by GPCR—NRAS—skin cancer	2.96e-06	0.00025	CbGpPWpGaD
Nortriptyline—HTR6—Signaling by GPCR—IL6—skin cancer	2.94e-06	0.000249	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—BRAF—skin cancer	2.92e-06	0.000247	CbGpPWpGaD
Nortriptyline—ALB—Metabolism—ERCC2—skin cancer	2.92e-06	0.000247	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—BRAF—skin cancer	2.91e-06	0.000246	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling by GPCR—HRAS—skin cancer	2.9e-06	0.000245	CbGpPWpGaD
Nortriptyline—ALB—Hemostasis—KRAS—skin cancer	2.89e-06	0.000245	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—BRAF—skin cancer	2.79e-06	0.000235	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling by GPCR—HRAS—skin cancer	2.78e-06	0.000235	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling by GPCR—IL6—skin cancer	2.78e-06	0.000235	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.75e-06	0.000233	CbGpPWpGaD
Nortriptyline—DRD2—Signaling by GPCR—NRAS—skin cancer	2.73e-06	0.000231	CbGpPWpGaD
Nortriptyline—PTGS1—Metabolism—PTGS2—skin cancer	2.73e-06	0.000231	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—ENO2—skin cancer	2.72e-06	0.00023	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling by GPCR—NRAS—skin cancer	2.69e-06	0.000227	CbGpPWpGaD
Nortriptyline—HRH1—Signaling by GPCR—NRAS—skin cancer	2.68e-06	0.000227	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling by GPCR—KRAS—skin cancer	2.68e-06	0.000226	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling by GPCR—NRAS—skin cancer	2.67e-06	0.000226	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling by GPCR—NRAS—skin cancer	2.66e-06	0.000225	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling by GPCR—KRAS—skin cancer	2.66e-06	0.000225	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling by GPCR—IL6—skin cancer	2.66e-06	0.000225	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling by GPCR—NRAS—skin cancer	2.64e-06	0.000223	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling by GPCR—NRAS—skin cancer	2.63e-06	0.000222	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—ERCC2—skin cancer	2.62e-06	0.000222	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling by GPCR—HRAS—skin cancer	2.61e-06	0.000221	CbGpPWpGaD
Nortriptyline—ALB—Hemostasis—TP53—skin cancer	2.57e-06	0.000217	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—BRAF—skin cancer	2.57e-06	0.000217	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling by GPCR—KRAS—skin cancer	2.55e-06	0.000216	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—BRAF—skin cancer	2.53e-06	0.000214	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—BRAF—skin cancer	2.52e-06	0.000213	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—BRAF—skin cancer	2.51e-06	0.000212	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—BRAF—skin cancer	2.5e-06	0.000212	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling by GPCR—IL6—skin cancer	2.5e-06	0.000211	CbGpPWpGaD
Nortriptyline—HTR6—Signaling Pathways—NRAS—skin cancer	2.48e-06	0.00021	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—BRAF—skin cancer	2.48e-06	0.00021	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—BRAF—skin cancer	2.47e-06	0.000209	CbGpPWpGaD
Nortriptyline—ALB—Hemostasis—HRAS—skin cancer	2.46e-06	0.000208	CbGpPWpGaD
Nortriptyline—CHRM3—Metabolism—PTGS2—skin cancer	2.42e-06	0.000205	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—ERCC2—skin cancer	2.41e-06	0.000204	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—ERCC2—skin cancer	2.39e-06	0.000202	CbGpPWpGaD
Nortriptyline—DRD2—Signaling by GPCR—KRAS—skin cancer	2.35e-06	0.000199	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—NRAS—skin cancer	2.34e-06	0.000198	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling by GPCR—KRAS—skin cancer	2.31e-06	0.000196	CbGpPWpGaD
Nortriptyline—HRH1—Signaling by GPCR—KRAS—skin cancer	2.31e-06	0.000195	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling by GPCR—KRAS—skin cancer	2.3e-06	0.000195	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling by GPCR—KRAS—skin cancer	2.29e-06	0.000194	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling by GPCR—HRAS—skin cancer	2.28e-06	0.000192	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling by GPCR—KRAS—skin cancer	2.27e-06	0.000192	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling by GPCR—KRAS—skin cancer	2.27e-06	0.000191	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling by GPCR—HRAS—skin cancer	2.26e-06	0.000191	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—NRAS—skin cancer	2.24e-06	0.00019	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling by GPCR—IL6—skin cancer	2.18e-06	0.000184	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling by GPCR—HRAS—skin cancer	2.17e-06	0.000183	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling by GPCR—IL6—skin cancer	2.17e-06	0.000183	CbGpPWpGaD
Nortriptyline—HTR6—Signaling Pathways—KRAS—skin cancer	2.14e-06	0.000181	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—NRAS—skin cancer	2.11e-06	0.000178	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling by GPCR—IL6—skin cancer	2.07e-06	0.000175	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—ERCC2—skin cancer	2.04e-06	0.000173	CbGpPWpGaD
Nortriptyline—CYP2E1—Metabolism—PTGS2—skin cancer	2.04e-06	0.000172	CbGpPWpGaD
Nortriptyline—CYP3A5—Metabolism—PTGS2—skin cancer	2.03e-06	0.000172	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—KRAS—skin cancer	2.02e-06	0.00017	CbGpPWpGaD
Nortriptyline—DRD2—Signaling by GPCR—HRAS—skin cancer	2e-06	0.000169	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling by GPCR—HRAS—skin cancer	1.97e-06	0.000166	CbGpPWpGaD
Nortriptyline—HRH1—Signaling by GPCR—HRAS—skin cancer	1.96e-06	0.000166	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling by GPCR—HRAS—skin cancer	1.96e-06	0.000165	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling by GPCR—HRAS—skin cancer	1.95e-06	0.000165	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling by GPCR—HRAS—skin cancer	1.93e-06	0.000163	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—KRAS—skin cancer	1.93e-06	0.000163	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling by GPCR—HRAS—skin cancer	1.93e-06	0.000163	CbGpPWpGaD
Nortriptyline—DRD2—Signaling by GPCR—IL6—skin cancer	1.91e-06	0.000162	CbGpPWpGaD
Nortriptyline—HTR6—Signaling Pathways—TP53—skin cancer	1.9e-06	0.000161	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling by GPCR—IL6—skin cancer	1.88e-06	0.000159	CbGpPWpGaD
Nortriptyline—HRH1—Signaling by GPCR—IL6—skin cancer	1.88e-06	0.000159	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling by GPCR—IL6—skin cancer	1.87e-06	0.000158	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling by GPCR—IL6—skin cancer	1.87e-06	0.000158	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling by GPCR—IL6—skin cancer	1.85e-06	0.000156	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling by GPCR—IL6—skin cancer	1.84e-06	0.000156	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—NRAS—skin cancer	1.84e-06	0.000155	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—NRAS—skin cancer	1.83e-06	0.000155	CbGpPWpGaD
Nortriptyline—HTR6—Signaling Pathways—HRAS—skin cancer	1.82e-06	0.000154	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—KRAS—skin cancer	1.82e-06	0.000153	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—TP53—skin cancer	1.79e-06	0.000151	CbGpPWpGaD
Nortriptyline—ALB—Metabolism—PTGS2—skin cancer	1.75e-06	0.000148	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—NRAS—skin cancer	1.75e-06	0.000148	CbGpPWpGaD
Nortriptyline—HTR6—Signaling Pathways—IL6—skin cancer	1.74e-06	0.000147	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—TP53—skin cancer	1.72e-06	0.000145	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—HRAS—skin cancer	1.71e-06	0.000145	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—HRAS—skin cancer	1.64e-06	0.000139	CbGpPWpGaD
Nortriptyline—CHRM4—Signaling Pathways—IL6—skin cancer	1.64e-06	0.000139	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—NRAS—skin cancer	1.61e-06	0.000136	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—TP53—skin cancer	1.61e-06	0.000136	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—NRAS—skin cancer	1.59e-06	0.000134	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—NRAS—skin cancer	1.58e-06	0.000134	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—KRAS—skin cancer	1.58e-06	0.000134	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—NRAS—skin cancer	1.58e-06	0.000134	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—ERCC2—skin cancer	1.58e-06	0.000133	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—NRAS—skin cancer	1.57e-06	0.000133	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—KRAS—skin cancer	1.57e-06	0.000133	CbGpPWpGaD
Nortriptyline—CYP2C19—Metabolism—PTGS2—skin cancer	1.57e-06	0.000133	CbGpPWpGaD
Nortriptyline—CHRM5—Signaling Pathways—IL6—skin cancer	1.57e-06	0.000133	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—NRAS—skin cancer	1.56e-06	0.000132	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—NRAS—skin cancer	1.55e-06	0.000131	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—HRAS—skin cancer	1.54e-06	0.00013	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—KRAS—skin cancer	1.51e-06	0.000127	CbGpPWpGaD
Nortriptyline—ADRA1D—Signaling Pathways—IL6—skin cancer	1.48e-06	0.000125	CbGpPWpGaD
Nortriptyline—CYP2D6—Metabolism—PTGS2—skin cancer	1.45e-06	0.000122	CbGpPWpGaD
Nortriptyline—CYP2C9—Metabolism—PTGS2—skin cancer	1.43e-06	0.000121	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—TP53—skin cancer	1.41e-06	0.000119	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—TP53—skin cancer	1.4e-06	0.000118	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—KRAS—skin cancer	1.39e-06	0.000117	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—KRAS—skin cancer	1.37e-06	0.000116	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—KRAS—skin cancer	1.36e-06	0.000115	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—KRAS—skin cancer	1.36e-06	0.000115	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—KRAS—skin cancer	1.35e-06	0.000115	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—HRAS—skin cancer	1.34e-06	0.000114	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—KRAS—skin cancer	1.34e-06	0.000113	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—TP53—skin cancer	1.34e-06	0.000113	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—KRAS—skin cancer	1.34e-06	0.000113	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—HRAS—skin cancer	1.34e-06	0.000113	CbGpPWpGaD
Nortriptyline—HTR1A—Signaling Pathways—IL6—skin cancer	1.29e-06	0.000109	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—HRAS—skin cancer	1.28e-06	0.000108	CbGpPWpGaD
Nortriptyline—HTR2C—Signaling Pathways—IL6—skin cancer	1.28e-06	0.000108	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—TP53—skin cancer	1.23e-06	0.000104	CbGpPWpGaD
Nortriptyline—CYP1A2—Metabolism—PTGS2—skin cancer	1.23e-06	0.000104	CbGpPWpGaD
Nortriptyline—ADRA1B—Signaling Pathways—IL6—skin cancer	1.23e-06	0.000104	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—TP53—skin cancer	1.21e-06	0.000103	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—TP53—skin cancer	1.21e-06	0.000102	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—TP53—skin cancer	1.21e-06	0.000102	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—TP53—skin cancer	1.2e-06	0.000102	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—TP53—skin cancer	1.19e-06	0.000101	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—TP53—skin cancer	1.19e-06	0.000101	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—HRAS—skin cancer	1.18e-06	9.98e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—HRAS—skin cancer	1.16e-06	9.82e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—HRAS—skin cancer	1.16e-06	9.8e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—HRAS—skin cancer	1.16e-06	9.77e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—HRAS—skin cancer	1.15e-06	9.74e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—HRAS—skin cancer	1.14e-06	9.64e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—HRAS—skin cancer	1.14e-06	9.61e-05	CbGpPWpGaD
Nortriptyline—DRD2—Signaling Pathways—IL6—skin cancer	1.13e-06	9.55e-05	CbGpPWpGaD
Nortriptyline—HTR2A—Signaling Pathways—IL6—skin cancer	1.11e-06	9.4e-05	CbGpPWpGaD
Nortriptyline—HRH1—Signaling Pathways—IL6—skin cancer	1.11e-06	9.38e-05	CbGpPWpGaD
Nortriptyline—CHRM1—Signaling Pathways—IL6—skin cancer	1.11e-06	9.35e-05	CbGpPWpGaD
Nortriptyline—CHRM3—Signaling Pathways—IL6—skin cancer	1.1e-06	9.32e-05	CbGpPWpGaD
Nortriptyline—CHRM2—Signaling Pathways—IL6—skin cancer	1.09e-06	9.23e-05	CbGpPWpGaD
Nortriptyline—ADRA1A—Signaling Pathways—IL6—skin cancer	1.09e-06	9.2e-05	CbGpPWpGaD
Nortriptyline—CYP3A4—Metabolism—PTGS2—skin cancer	9.46e-07	8e-05	CbGpPWpGaD
